Precision Oncology
Axovia Therapeutics, Viralgen Partner on Bardet-Biedl Syndrome Gene Therapy
The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
Galapagos Inks Deal With Catalent to Use New Jersey Site for Decentralized Cell Therapy Trials
The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new approach to base editing.